Approval · Notice of Compliance 33252 · 2024
SIMULECT: Notice of Compliance 33252
Issued May 17, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33252
- Date
- May 17, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a new manufacturing site for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMULECT | Not yet assigned | — |
Medicinal ingredients
- BASILIXIMAB 20 MG per VIAL